Bioxytran Inc Stock Price, News & Analysis

Bioxytran (OTCQB: BIXT) has signed a Non-Disclosure Agreement with the University of Georgia to evaluate its galectin antagonists as a potential treatment for bird flu in chickens. The research collaboration will be led by Dr. Daniel Perez, an expert in virology and poultry medicine who serves as CVI Affiliated Faculty and Caswell Eidson Chair in Poultry Medicine at the university.

The company's leading drug candidate, ProLectin-M, is a galectin antagonist designed to fight viral infections by targeting galectins - proteins involved in viral replication, inflammation, and fibrosis. The drug has shown promise in in vitro studies against viruses similar to the bird flu virus, suggesting potential applications in poultry treatment.

Bioxytran (OTCQB: BIXT) has announced a potential breakthrough in treating Bird Flu (H5N1) in egg-laying chickens through a new water-soluble galectin antagonist currently in preclinical trials. The treatment aims to prevent the need for mass culling during outbreaks by blocking viral entry into cells.

The company's approach leverages galectin antagonists that neutralize the virus by blocking viral adhesion, a mechanism previously demonstrated in Phase 2 human clinical trials and in vitro tests. The carbohydrate-based treatment targets viral spike proteins, preventing them from connecting to cells, potentially offering immediate containment of outbreaks.

This development could significantly impact the poultry industry, which currently faces billions in annual losses due to Bird Flu outbreaks and mandatory culling protocols. Bioxytran is actively seeking partnerships with organizations and government agencies to accelerate the treatment's development and deployment.

Bioxytran (OTCQB: BIXT) has secured a $1.6 million common stock purchase agreement with TRITON FUNDS LP, marking their second and larger investment in the company. The funding will serve two main purposes: $805,000 will be used to settle an existing convertible note, while the remaining amount will support regulatory pre-clinical and clinical trials and working capital needs.

Additionally, the company's management is forfeiting accrued salaries and expenses worth over $460,000. The investment aims to advance Bioxytran's development of Galectin Antagonists and support their FDA trial of PLM, while also enabling testing of various pandemic-potential viruses to demonstrate their broad-spectrum antiviral capability.

Bioxytran (OTCQB: BIXT) has released a preprint article exploring the potential enhancement of cancer immunotherapy through galectin-3 modulation. The research focuses on improving Immune Checkpoint Inhibitors (ICIs) effectiveness in cancer treatment. Key findings show that high galectin-3 levels correlate with treatment failure, with 90% of Non-Small Cell Lung Cancer patients with elevated levels failing to respond after three treatments.

The study reveals that galectin-3 protein interferes with ICI therapy by occupying the antibody's PD-1 receptor binding site, preventing effective treatment. However, in vitro tests indicate that galectin-3 antagonists could potentially reverse this effect. The company also published a presentation on cancer metastasis, highlighting the 'Galectin Effect' as cancer's primary defense mechanism against immune response.

Bioxytran (OTCQB: BIXT) held a significant Techwatch Light meeting with BARDA, attracting over 65 government personnel from various agencies including CDMRP, NIAID, NIH, DTRA, and DoD. The company presented four key Areas of Interest: influenza antiviral, immune modulators for lung repair, solutions for uncontrolled hemorrhaging, and a versatile strategic therapeutic.

The meeting focused primarily on discussions about the influenza antiviral and Universal Oxygen Carrier. BARDA provided guidance on program qualification requirements and potential funding opportunities. The company received feedback on development stages and supporting data needed for specific programs, marking a strategic step toward securing government funding for clinical trial development.

Bioxytran (OTCQB:BIXT) has announced a significant breakthrough in virology, validated in a peer-reviewed journal article. The company's drug candidate, Prolectin-M, has shown effectiveness in stopping COVID-19 and other viruses by blocking galectin, a protein important for viral attachment to cells. This discovery, made using advanced Nuclear Magnetic Resonance (NMR) spectroscopy, could impact both the antiviral and vaccination markets, collectively valued at approximately $147 billion.

The study revealed that galectins, located on the virus's spike protein, are an excellent drug target due to their stability. This could lead to the development of broad-spectrum antivirals effective against various viruses. Bioxytran's CEO, Dr. David Platt, believes this discovery represents a new era in antiviral drug development, potentially revolutionizing the treatment of viral diseases and even chronic illnesses like cancer.

Bioxytran (OTCQB: BIXT) has formed a Joint Venture with the Heme Foundation to develop a Universal Oxygen Carrier (UOC) as an alternative to blood transfusions. The Foundation pledged up to $10 million for the project, with $2 million already invested in prototypes and compound development. Bioxytran retains all intellectual property rights, while the Foundation gains usage rights for blood transfusion applications.

The UOC, a hemoglobin-based oxygen carrier, is designed to be compatible with all blood types, pathogen-free, and shelf-stable at room temperature for 5+ years. It has shown promise in small-scale animal trials and is preparing for a large-scale toxicology study. This technology could revolutionize transfusion medicine, particularly in remote areas with blood supply infrastructure.

Bioxytran's Science Advisor, Prof. Avraham Mayevsky, has published a book titled Hyperbaric Oxygenation Mitochondrial Activity and Brain Physiological Functions. The book, available as an eBook or hardcover from Springer, delves into the impact of hyperbaric oxygen on brain functions, particularly mitochondrial activity.

Central to the book is the MDX Viewer, an FDA-approved device that measures tissue oxygenation at the cellular level. The device's output, the Brain Metabolic Score (BMS), is essential for Bioxytran's acellular oxygen carrier (AOC) molecule, BXT-25, which is being developed for ischemic stroke and Alzheimer's disease treatments. Bioxytran aims to use BXT-25 to replace hyperbaric oxygen treatment (HBOT) in clinical trials.

The book offers a comprehensive overview of how hyperbaric oxygen impacts brain biochemical and physiological responses, influencing mitochondrial activity and enhancing brain functions.